High-content multiplexed tissue imaging and quantification for cancer drug discovery

Drug Discovery Today

Volumn 18, Issue 11-12, 2013, Pages 510-522

  Falcon, Beverly L ^a   Stewart, Julie ^a   Ezell, Scharri ^a   Hanson, Jeff ^a   Wijsman, John ^a   Ye, Xiang ^a   Westin, Eric ^a   Donoho, Greg ^a   Credille, Kelly ^a   Uhlik, Mark T ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; LITRONESIB; SORAFENIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER TISSUE; CELL HYPOXIA; CELL PROLIFERATION; CONCENTRATION RESPONSE; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LABORATORY AUTOMATION; NONHUMAN; PHENOTYPE; PROTEIN TARGETING; REVIEW; TARGET CELL; TISSUE SECTION; TUMOR MODEL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84878872860     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.08.008     Document Type: Review

References (39)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
3. J.M. Ebos Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
4. M. Paez-Ribes Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
5. G. Bergers Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295
6. G. Bocci Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib Br. J. Cancer 98 2008 1619 1629
7. B.L. Falcon Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B Am. J. Pathol. 178 2011 2920 2930
8. H. Hashizume Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth Cancer Res. 70 2010 2213 2223
9. T. Inai Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am. J. Pathol. 165 2004 35 52
10. H. Iwamoto Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma Neoplasia 13 2011 187 197
11. T. Meier Tasisulam Sodium, an anti-tumor agent that inhibits mitotic progression and induces vascular normalization Mol. Cancer Ther. 10 2011 2168 2178
12. I. Noguera-Troise Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis Nature 444 2006 1032 1037
13. J. Ridgway Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis Nature 444 2006 1083 1087
14. B. Sennino Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102 Cancer Res. 67 2007 7358 7367
15. S. Song PDGFRbeta1 perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nat. Cell Biol. 7 2005 870 879
16. F. Winkler Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
17. J. Folkman Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment Ann. Surg. 164 1966 491 502
18. G. Allt, and J.G. Lawrenson Pericytes: cell biology and pathology Cells Tissues Organs 169 2001 1 11
19. K.K. Hirschi, and P.A. D'Amore Pericytes in the microvasculature Cardiovasc. Res. 32 1996 687 698
20. D. von Tell Pericytes and vascular stability Exp. Cell Res. 312 2006 623 629
21. B.L. Falcon Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels Am. J. Pathol. 175 2009 2159 2170
22. P. Baluk Cellular abnormalities of blood vessels as targets in cancer Curr. Opin. Genet. Dev. 15 2005 102 111
23. R.T. Tong Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64 2004 3731 3736
24. V.A. Carroll, and M. Ashcroft Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway Cancer Res. 66 2006 6264 6270
25. S. Pennacchietti Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
26. M.U. Baumann Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1 Am. J. Physiol. Cell Physiol. 293 2007 C477 C485
27. C. Chen Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia J. Biol. Chem. 276 2001 9519 9525
28. A. Ouiddir Hypoxia upregulates activity and expression of the glucose transporter GLUT1 in alveolar epithelial cells Am. J. Respir. Cell Mol. Biol. 21 1999 710 718
29. D.G. Hirst Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate Br. J. Cancer 64 1991 54 58
30. J.A. Wijsman A practical method to determine the amount of tissue to analyse using laser scanning cytometry Cytometry A 71 2007 501 508
31. M.R. Mancuso Rapid vascular regrowth in tumors after reversal of VEGF inhibition J. Clin. Invest. 116 2006 2610 2621
32. F. Kuhnert Dll4-Notch signaling as a therapeutic target in tumor angiogenesis Vasc. Cell 3 2011 20
33. Y.S. Chang Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother. Pharmacol. 59 2007 561 574
34. S. Kim Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Mol. Cancer Ther. 6 2007 1785 1792
35. L. Liu Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res. 66 2006 11851 11858
36. H. Huynh Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation Curr. Cancer Drug Targets 11 2011 944 953
37. M.A. Esteve Microtubules in apoptosis induction: are they necessary? Curr. Cancer Drug Targets 7 2007 713 729
38. E. Koller Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development Cancer Res. 66 2006 2059 2066
39. M. Liu Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor Biochem. Pharmacol. 76 2008 169 178